Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells
Biomolecules · 2025
DOI: 10.3390/biom15091245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Yalda Hekmatshoar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, School of Medicine, Altinbas University, 34147 Istanbul, Turkey. Hauptthemen laut MEDLINE: Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Resistance, Neoplasm, Integrin alpha2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Projects Unit of Altinbas University.
Abstract (Originalsprache)
Chronic myeloid leukemia (CML) is a blood disorder caused by a genetic alteration that creates the BCR-ABL fusion gene, leading to continuous activation of cell growth signals and uncontrolled proliferation of the blood cells. Imatinib (IMA) resistance remains a major obstacle in CML treatment. Integrins, particularly integrin α2 (ITGA2), have been associated with cancer progression and drug resistance. In the current study, we investigated the role of ITGA2 in IMA resistance using IMA-sensitive K562 (K562S) and IMA-resistant K562 (K562R) cells. Our findings showed that ITGA2 is overexpressed in K562R cells and ITGA2 inhibitor E7820 (2.5 µM) treatment significantly decreased cell viability and induced apoptosis in both sensitive and resistant cells. Combination treatment with E7820 and imatinib enhanced pro-apoptotic gene expression (BAX, BIM) and decreased anti-apoptotic BCL2 levels in imatinib-resistant K562R cells. Flow cytometry confirmed ITGA2 inhibition at the protein level, and rhodamine assays revealed reduced MDR1 activity in treated cells. These results demonstrate that targeting ITGA2 may overcome imatinib resistance and offer a novel therapeutic strategy for CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, School of Medicine, Altinbas University, 34147 Istanbul, Turkey.
- Department of Medical Biology, School of Medicine, Ankara University, 06230 Ankara, Turkey.
- Department of Biochemistry, Faculty of Pharmacy, Ankara University, 06560 Ankara, Turkey.
- Department of Medical Biology, School of Medicine, Istinye University, 34396 Istanbul, Turkey.
- Department of Medical Biology, Gulhane Faculty of Medicine, Health Sciences University, 06018 Ankara, Turkey.
- Central Research Laboratory, Altinbas University, 34147 Istanbul, Turkey.
ORCID-Profile: Yalda Hekmatshoar
Förderung
- Scientific Research Projects Unit of Altinbas University
Zitieren
APA
Hekmatshoar, Y., Ozkan, T., Karabay, A. Z., Bozkurt, S., Gurel, A. K., Gomleksiz, O. K., Fisgin, T., & Sunguroglu, A. (2025). Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells. Biomolecules. https://doi.org/10.3390/biom15091245
Vancouver
Hekmatshoar Y, Ozkan T, Karabay AZ, Bozkurt S, Gurel AK, Gomleksiz OK, et al. Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells. Biomolecules. 2025. doi:10.3390/biom15091245
BibTeX
@article{Hekmatshoar2025,
author = {Hekmatshoar, Yalda and Ozkan, Tulin and Karabay, Arzu Zeynep and Bozkurt, Sureyya and Gurel, Aynur Karadag and Gomleksiz, Ozlem Kurnaz and Fisgin, Tunc and Sunguroglu, Asuman},
title = {Targeting Integrin α2 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15091245}
}
EUVIMED